Regeneron Pharmaceuticals, Inc.
) recently presented data from two phase Ib trials evaluating
dupilumab (REGN668/SAR231893) for moderate-to-severe atopic
dermatitis (AD) who did not receive sufficient benefit with
existing topical treatments. The data was presented at the annual
meeting of the American Academy of Dermatology.
LILLY ELI & CO (LLY): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
The randomized phase Ib trials (n = 67) assessed the safety of
dupilumab in three different doses (75mg, 150mg, 300mg) for 8
weeks. The companies also evaluated dupilumab in other parameters
including efficacy, pharmacokinetic and biomarker.
The results showed that nasopharyngitis and headache were the
most common side effects associated with the use of dupilumab.
The efficacy profile of the candidate was encouraging.
Sanofi and Regeneron plan to present data from a 12-week phase 2a
trial and a phase 2b trial evaluating dupilumab for AD later in
2013. We note that the companies are also evaluating the
candidate for eosinophilic asthma (phase II).
Sanofi and Regeneron have a successful partnership history since
2003. The companies are collaborating for Zaltrap (aflibercept),
which is approved both in the US (Aug 2012) and EU (Feb 2013) as
a combination therapy (with 5-fluorouracil, leucovorin,
irinotecan - FOLFIRI) for treating patients suffering from
metastatic colorectal cancer who are either resistant or whose
disease has progressed following treatment with an
Sanofi and Regeneron both carry a Zacks Rank #3 (Hold) in the
short run. Right now,
Eli Lilly and Company
) look more attractive in the pharma space with a Zacks Rank #2